CV-Homes: Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness

Sponsor
Hennepin Healthcare Research Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06025721
Collaborator
National Institutes of Health (NIH) (NIH), University of Minnesota (Other), National Institute on Minority Health and Health Disparities (NIMHD) (NIH)
8
1
1
9
0.9

Study Details

Study Description

Brief Summary

This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cardiovascular Risk Homeless Support
N/A

Detailed Description

This study is of a set of studies with an overall goal to develop and pilot test a collaborative care intervention using motivational interviewing and behavioral activation alongside education and psychosocial support to improve medication adherence tailored to the experiences of people experiencing homelessness and cardiovascular health risks (CV-H). Our team's central hypothesis is that medication adherence and cardiovascular self-care (and eventual glycemic control, cholesterol control, health care use/cost) will improve with an intervention tailored to the unique context of CV-H.

This protocol addresses a pilot study to test patient perceptions of the feasibility and acceptability of study procedures and refine the CV-Homes treatment manual through test cases (n=8). With a hypothesis that the CV-Homes manual and study procedures will be feasible and acceptable to CV-H as measured by self-report and post-treatment interview.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
8 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This will be an in-person, phone, or video based behavioral intervention. It will involve a wellness coach assisting participants to set goals related to diabetes self-care and co-morbitities or social conditions that get in the way of health and wellness. There will be encouragement to work on medication adherence and to address getting healthy sleep, quitting tobacco, being more active, and eating better.This will be an in-person, phone, or video based behavioral intervention. It will involve a wellness coach assisting participants to set goals related to diabetes self-care and co-morbitities or social conditions that get in the way of health and wellness. There will be encouragement to work on medication adherence and to address getting healthy sleep, quitting tobacco, being more active, and eating better.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Development of a Multiple Health Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness: The CV-HOMES Study
Actual Study Start Date :
May 25, 2023
Anticipated Primary Completion Date :
Feb 23, 2024
Anticipated Study Completion Date :
Feb 23, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: CV-Homes Intervention

Behavioral treatment by a wellness coach.

Behavioral: Cardiovascular Risk Homeless Support
There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed.
Other Names:
  • CV-Homes
  • Outcome Measures

    Primary Outcome Measures

    1. Acceptability Measured by the Client Satisfaction Questionnaire [at 16 weeks]

      This will be assessed at the end of the intervention using the 8-item Client Satisfaction Questionnaire, with a score range 8-32, higher score indicating greater satisfaction.

    2. Treatment Engagement Measured by Sessions Attended [At 16 weeks]

      Throughout the study we will measure engagement by tracking attendance of treatment sessions.

    Secondary Outcome Measures

    1. Health-related quality of life [Baseline to 16 weeks]

      Health related quality of life as measured by the Euro-Qol 5D-5-L which asks 5 questions on a 5-response likert scale with 1 = no problems and 5= unable to; and one question on a scale of 1-100 with 1 being the worst health one can imagine and 100 being the best health one can imagine.

    2. Hemoglobin A1c [Baseline to 16 weeks]

      Change in point-of-care hemoglobin A1c

    3. Total cholesterol [Baseline to 16 weeks]

      Change in point-of-care cholesterol

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18 yrs. or older

    • English-speaking

    • Homelessness by federal definition in the last 12 mo.

    • Self-reported diagnosis of moderate or high CVD risk, defined as being told by a medical professional that the participant has hypertension, prediabetes, type 2 diabetes, or heart disease

    • Plan to stay in local area or be reachable by phone for the next 16 weeks

    • Willingness to work on one or more CVD risk reduction behavior change

    Exclusion Criteria:
    • Active intoxication

    • Active psychosis

    • Presence of a legal guardian

    • Pregnant or lactating people

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hennepin Healthcare Research Institute Minneapolis Minnesota United States 55404

    Sponsors and Collaborators

    • Hennepin Healthcare Research Institute
    • National Institutes of Health (NIH)
    • University of Minnesota
    • National Institute on Minority Health and Health Disparities (NIMHD)

    Investigators

    • Principal Investigator: Katherine D Vickery, MD, Hennepin Healthcare Research Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hennepin Healthcare Research Institute
    ClinicalTrials.gov Identifier:
    NCT06025721
    Other Study ID Numbers:
    • IRB-FY2022-373
    • P50MD017342
    First Posted:
    Sep 6, 2023
    Last Update Posted:
    Sep 6, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hennepin Healthcare Research Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 6, 2023